Serum CTRP3 and RBP4 Levels in Obesity and Hypertension

NCT ID: NCT02226471

Last Updated: 2014-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insulin resistance is closely correlated with obesity and cardiovascular disease. Adipokines may play important roles in the pathogenesis of obesity, which are a link between obesity and obesity-related disorders.C1q/TNF-related protein-3 (CTRP3) and retinol-binding protein 4 (RBP4) are novel adipokine that modulates the action of insulin in various diseases. This study addressed the relationship between CTRP3, RBP4 and IR in newly diagnosed obesity and essential hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Serum CTRP3 and RBP4, anthropometric and metabolic parameters were determined in 480 newly diagnosed obesity and essential hypertensive patients not taking anti-obese and antihypertensive medications and 66 normal weight (NW) and normotensive subjects. All subjects were divided into two groups depending on body mass index (BMI), including NW group and obesity group, and then four subgroups were divided according to obesity and hypertension, including NW-normal blood pressure subgroup (NW-NBP), NW-hypertension subgroup (NW-HTN), obese-normal blood pressure subgroup (OB-NBP), obese-hypertension subgroup (OB-HTN).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NW-NBP group

normal weight and blood pressure subjects

No interventions assigned to this group

NW-HTN group

Normal weight with hypertension subjects

No interventions assigned to this group

OB-NBP group

obese-normal blood pressure subjects

No interventions assigned to this group

OB-HTN group

Obese-hypertension subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Hypertension not taking antihypertensive medications
2. Obesity not taking anti-obese or lipid-lowering medications

Exclusion Criteria

1. Heart failure;
2. pregnant or lactating
3. diabetes
4. thyroid disease
5. fractures
6. osteoporosis
7. tumors;
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Third Military Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Deng Wu Quan

Chongqing southwest hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deng Wuquan, PHD

Role: STUDY_DIRECTOR

Southwest Hospital, China

References

Explore related publications, articles, or registry entries linked to this study.

Deng W, Li C, Zhang Y, Zhao J, Yang M, Tian M, Li L, Zheng Y, Chen B, Yang G. Serum C1q/TNF-related protein-3 (CTRP3) levels are decreased in obesity and hypertension and are negatively correlated with parameters of insulin resistance. Diabetol Metab Syndr. 2015 Apr 10;7:33. doi: 10.1186/s13098-015-0029-0. eCollection 2015.

Reference Type DERIVED
PMID: 25878729 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0055744

Implication of Progranulin and C1q/TNF-Related Protein-3 (CTRP3) on Inflammation and Atherosclerosis in Subjects with or without Metabolic Syndrome

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0099785

Identification of Adipokine Clusters Related to Parameters of Fat Mass, Insulin Sensitivity and Inflammation

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SW1000

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Adiposity and Endothelin Receptor Function
NCT03583866 ACTIVE_NOT_RECRUITING EARLY_PHASE1